LearnGlossaryMarketStocksSuperinvestorsSign in

PHAT

Phathom Pharmaceuticals, Inc.

Healthcare · $595M market cap

Verdict

We can't put a fair value on PHAT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-66.6% a year✗
Sales growth216.9% a year✓
Free cash flow growth—?
Return on invested capital-72.7%✗

Follow PHAT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Breedlove Robert Charles

Principal Accounting Officer · 2026-09-03

Tax withholding

$4K

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works